Skip to content
Research platform
  • Company
    • About us
    • Team
  • Products
    • CNS tumour methylation classifier
    • Sarcoma methylation classifier
    • Skin cancer methylation classifier
  • Research
    • Methylation classification
    • Histology AI
  • News
  • Resources
    • Info materials
    • Publications
    • Events calendar
    • Frequently asked questions
Research platform
  • Company
    • About us
    • Team
  • Products
    • CNS tumour methylation classifier
    • Sarcoma methylation classifier
    • Skin cancer methylation classifier
  • Research
    • Methylation classification
    • Histology AI
  • News
  • Resources
    • Info materials
    • Publications
    • Events calendar
    • Frequently asked questions

methylation classifier

  • 1 June 2026

    Heidelberg Epignostix appoints co-founder Prof. Dr. Dr. med. Felix Sahm as Chief Medical Advisor

    Prof. Dr. Dr. med. Felix Sahm joins as Chief Medical Advisor, guiding clinical and medical strategy as the company expands its precision diagnostics portfolio.

  • 8 July 2025

    Epignostix launches advanced DNA methylation-based sarcoma classifier

    A substantial update to the sarcoma tumour classifier, extending precision methylation-based classification beyond tumours of the central nervous system.

AI-powered insights for precision oncology

Heidelberg Epignostix GmbH
c/o BioLabs Heidelberg
Nikola-Tesla-Straße 1
69124 Heidelberg

Company
  • About us
  • Team
  • News
  • Contact us
Products
  • CNS tumour classifier
  • Sarcoma classifier
  • Skin cancer classifier
Research
  • Methylation classification
  • Histology AI
  • Research platform
Resources
  • Info materials
  • Publications
  • Events calendar
  • Frequently asked questions
Legal notice
  • Privacy Policy
  • Imprint
  • Disclaimer
  • Terms of Use

© 2026 • Heidelberg Epignostix GmbH • All Rights Reserved

Page load link
Go to Top